It is currently in Phase III clinical trials. Primary use is for the treatment of indolent and aggressive NHLs. Every year there are 56,000 newly diagnosed cases and 25,000 deaths. It is currently in Phase I clinical trials. Naked humanized antibody targeting CEA-expressing tumors.
Primary use is for the treatment of inoperable metastatic solid tumors.
It is currently in Phase I clinical trials. Primary use is for the treatment of inoperable metastatic solid tumors. It is currently in Phase I clinical trials. A complication of hepatitis, hepatocellular carcinoma is not common in the United States, but is one of the most common cancers worldwide, due to its high rate in Asia. It is in preclinical development.